A Phase 1 interventional study of EIDD-2801 and Placebo in Coronavirus, sponsored by Ridgeback Biotherapeutics, LP. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-19.
Sponsored by Ridgeback Biotherapeutics, LP · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Coronavirus Infections with a site in United Kingdom — 2 open to participants now, 3 under way, 1 of them phase 3. Coronavirus Infections · United Kingdom.
Among the 69 studies in Coronavirus Infections with a site in United Kingdom, this one is the 32nd largest by enrollment of the 44 interventional ones that give a count, is one of 52 that started in 2020, is one of 7 in phase 1, and was the 18th registered.
1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.
Browse Coronavirus Infections studies →2 of the 69 studies in Coronavirus Infections with a site in United Kingdom are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United Kingdom, United States, Argentina and 36 more countries
Ages 18+
University of Oxford · Sites in United Kingdom
Ages 18–100 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 17 · Phase 4 1
First in 2018; this study’s year is marked. 52 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is close to the median of 120 across 655 interventional studies indexed under Coronavirus Infections.
Median enrollment 360 across the 44 interventional studies, 442 across the 25 observational. Of the 54 that completed or were terminated, 23 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 69 have an industry lead sponsor. The 10 most frequent:
Ridgeback Biotherapeutics, LP is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Ridgeback Biotherapeutics, LP has 1 study filed under Coronavirus Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Coronavirus Infections with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add it to your calendar (.ics) → With an account.
Among the 69 studies in Coronavirus Infections with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a First In Human study designed to assess the safety, tolerability and pharmacokinetics of EIDD-2801 in healthy human volunteers.
This is a randomized, double-blind, placebo-controlled, First-in-Human study designed to evaluate the safety, tolerability, and pharmacokinetics of EIDD-2801 following oral administration to healthy volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EIDD-2801: Part 1: Participants were randomized to receive 50 to 1600 mg EIDD-2801 powder-in bottle (fasted); Part 2: Participants were randomized to receive two single 200 mg doses (fed or fasted); Part 3: Participants were randomized to receive twice daily doses of EIDD-2801 in an open-label manner.
Drug: EIDD-2801
Placebo: Part 1: Participants were randomized to receive placebo (fasted); Part 3: Participants were randomized to receive placebo (fasted).
Drug: Placebo
Part 1: Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo. Part 2: Two single oral doses of EIDD-2801 will be administered to participants, in an open-label manner. Part 3: Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.
Also known as: Molnupiravir
Part 1: Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo. Part 3: Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.
Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events
Number of participants with treatment emergent adverse events (TEAEs) and severity of TEAEs following a single dose of EIDD-2801 in Part 1
Time frame: From screening through study completion, up to 15 days
Part 3: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events
Number of participants with treatment emergent adverse events (TEAEs) and severity of TEAEs following multiple doses of EIDD-2801 in Part 3
Time frame: From screening through study completion, up to 20 days
| Milestone | Part 1 - Placebo | Part 1 - 50 mg EIDD-2801 | Part 1 - 100 mg EIDD-2801 | Part 1 - 200 mg EIDD-2801 | Part 1 - 400 mg EIDD-2801 | Part 1 - 600 mg EIDD-2801 | Part 1 - 800 mg EIDD-2801 | Part 1 - 1200 mg EIDD-2801 | Part 1 - 1600 mg EIDD-2801 | Part 2 - 200 mg EIDD-2801 (Fasted/Fed) | Part 3 - Placebo | Part 3 - 50 mg EIDD-2801 | Part 3 - 100 mg EIDD-2801 | Part 3 - 200 mg EIDD-2801 | Part 3 - 300 mg EIDD-2801 | Part 3 - 400 mg EIDD-2801 | Part 3 - 600 mg EIDD-2801 | Part 3 - 800 mg EIDD-2801 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 10 | 14 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Completed | 16 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 10 | 14 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with treatment emergent adverse events (TEAEs) and severity of TEAEs following a single dose of EIDD-2801 in Part 1
| Participants | Part 1 - Placebo | Part 1 - 50 mg EIDD-2801 | Part 1 - 100 mg EIDD-2801 | Part 1 - 200 mg EIDD-2801 | Part 1 - 400 mg EIDD-2801 | Part 1 - 600 mg EIDD-2801 | Part 1 - 800 mg EIDD-2801 | Part 1 - 1200 mg EIDD-2801 | Part 1 - 1600 mg EIDD-2801 |
|---|---|---|---|---|---|---|---|---|---|
| TEAEs (Overall) | 7 | 2 | 0 | 3 | 3 | 4 | 2 | 1 | 2 |
| Mild (Grade 1) | 7 | 2 | 0 | 3 | 3 | 4 | 2 | 1 | 2 |
| Moderate (Grade 2) | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Severe (Grade 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with treatment emergent adverse events (TEAEs) and severity of TEAEs following multiple doses of EIDD-2801 in Part 3
| Participants | Part 3 - Placebo | Part 3 - 50 mg EIDD-2801 | Part 3 - 100 mg EIDD-2801 | Part 3 - 200 mg EIDD-2801 | Part 3 - 300 mg EIDD-2801 | Part 3 - 400 mg EIDD-2801 | Part 3 - 600 mg EIDD-2801 | Part 3 - 800 mg EIDD-2801 |
|---|---|---|---|---|---|---|---|---|
| TEAEs (Overall) | 7 | 2 | 3 | 3 | 2 | 3 | 2 | 3 |
| Mild (Grade 1) | 7 | 2 | 3 | 3 | 2 | 3 | 2 | 3 |
| Moderate (Grade 2) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Severe (Grade 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over From the time of the first study drug administration until the completion of the End of Study visit (Part 1: approximately 15 days, Part 2: approximately 30 days, and Part 3: approximately 20 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 - Placebo | 0/16 (0%) | 0/16 (0%) | 7/16 (43.8%) |
| Part 1 - 50 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1 - 100 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part 1 - 200 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 1 - 400 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 1 - 600 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 1 - 800 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1 - 1200 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1 - 1600 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 2 - 200 mg EIDD-2801 (Fasted) | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Part 2 - 200 mg EIDD-2801 (Fed) | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Part 3 - Placebo | 0/14 (0%) | 0/14 (0%) | 7/14 (50%) |
| Part 3 - 50 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 3 - 100 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 3 - 200 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 3 - 300 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 3 - 400 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 3 - 600 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 3 - 800 mg EIDD-2801 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Event | Part 1 - Placebo | Part 1 - 50 mg EIDD-2801 | Part 1 - 100 mg EIDD-2801 | Part 1 - 200 mg EIDD-2801 | Part 1 - 400 mg EIDD-2801 | Part 1 - 600 mg EIDD-2801 | Part 1 - 800 mg EIDD-2801 | Part 1 - 1200 mg EIDD-2801 | Part 1 - 1600 mg EIDD-2801 | Part 2 - 200 mg EIDD-2801 (Fasted) | Part 2 - 200 mg EIDD-2801 (Fed) | Part 3 - Placebo | Part 3 - 50 mg EIDD-2801 | Part 3 - 100 mg EIDD-2801 | Part 3 - 200 mg EIDD-2801 | Part 3 - 300 mg EIDD-2801 | Part 3 - 400 mg EIDD-2801 | Part 3 - 600 mg EIDD-2801 | Part 3 - 800 mg EIDD-2801 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/16 | 1/6 | 0/6 | 0/6 | 1/6 | 3/6 | 1/6 | 0/6 | 0/6 | 0/10 | 0/10 | 0/14 | 0/6 | 1/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 |
| Feeling hotGeneral disorders | 0/16 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/10 | 0/14 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Back painMusculoskeletal and connective tissue disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 | 0/6 | 0/10 | 0/10 | 0/14 | 0/6 | 2/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
| LymphadenopathyBlood and lymphatic system disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/10 | 0/10 | 0/14 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Ear painEar and labyrinth disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/10 | 0/10 | 0/14 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| TinnitusEar and labyrinth disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/10 | 0/10 | 0/14 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Abnormal sensation in eyeEye disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/10 | 0/14 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Eye irritationEye disorders | 0/16 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/10 | 0/14 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/16 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/10 | 0/14 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Abdominal pain upperGastrointestinal disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/10 | 0/14 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
Safety population
| Age, Continuous(years) | Part 1 - Placebo | Part 1 - 50 mg EIDD-2801 | Part 1 - 100 mg EIDD-2801 | Part 1 - 200 mg EIDD-2801 | Part 1 - 400 mg EIDD-2801 | Part 1 - 600 mg EIDD-2801 | Part 1 - 800 mg EIDD-2801 | Part 1 - 1200 mg EIDD-2801 | Part 1 - 1600 mg EIDD-2801 | Part 2 - 200 mg EIDD-2801 (Fasted/Fed) | Part 3 - Placebo | Part 3 - 50 mg EIDD-2801 | Part 3 - 100 mg EIDD-2801 | Part 3 - 200 mg EIDD-2801 | Part 3 - 300 mg EIDD-2801 | Part 3 - 400 mg EIDD-2801 | Part 3 - 600 mg EIDD-2801 | Part 3 - 800 mg EIDD-2801 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 39.4 (22 to 56) | 52.0 (34 to 57) | 41.2 (23 to 58) | 39.8 (26 to 60) | 42.0 (23 to 57) | 38.2 (21 to 57) | 39.5 (23 to 56) | 34.2 (24 to 56) | 30.8 (25 to 46) | 45.3 (30 to 60) | 37.5 (19 to 59) | 34.0 (23 to 56) | 45.5 (20 to 58) | 36.8 (22 to 60) | 36.2 (20 to 58) | 38.8 (20 to 60) | 30.8 (20 to 54) | 30.8 (20 to 58) | 38.7 (19 to 60) |
| Sex: Female, Male(Participants) | Part 1 - Placebo | Part 1 - 50 mg EIDD-2801 | Part 1 - 100 mg EIDD-2801 | Part 1 - 200 mg EIDD-2801 | Part 1 - 400 mg EIDD-2801 | Part 1 - 600 mg EIDD-2801 | Part 1 - 800 mg EIDD-2801 | Part 1 - 1200 mg EIDD-2801 | Part 1 - 1600 mg EIDD-2801 | Part 2 - 200 mg EIDD-2801 (Fasted/Fed) | Part 3 - Placebo | Part 3 - 50 mg EIDD-2801 | Part 3 - 100 mg EIDD-2801 | Part 3 - 200 mg EIDD-2801 | Part 3 - 300 mg EIDD-2801 | Part 3 - 400 mg EIDD-2801 | Part 3 - 600 mg EIDD-2801 | Part 3 - 800 mg EIDD-2801 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 0 | 0 | 3 | 2 | 1 | 1 | 0 | 2 | 1 | 0 | 0 | 21 |
| Male | 14 | 4 | 4 | 5 | 4 | 4 | 6 | 6 | 6 | 7 | 12 | 5 | 5 | 6 | 4 | 5 | 6 | 6 | 109 |
| Race (NIH/OMB)(Participants) | Part 1 - Placebo | Part 1 - 50 mg EIDD-2801 | Part 1 - 100 mg EIDD-2801 | Part 1 - 200 mg EIDD-2801 | Part 1 - 400 mg EIDD-2801 | Part 1 - 600 mg EIDD-2801 | Part 1 - 800 mg EIDD-2801 | Part 1 - 1200 mg EIDD-2801 | Part 1 - 1600 mg EIDD-2801 | Part 2 - 200 mg EIDD-2801 (Fasted/Fed) | Part 3 - Placebo | Part 3 - 50 mg EIDD-2801 | Part 3 - 100 mg EIDD-2801 | Part 3 - 200 mg EIDD-2801 | Part 3 - 300 mg EIDD-2801 | Part 3 - 400 mg EIDD-2801 | Part 3 - 600 mg EIDD-2801 | Part 3 - 800 mg EIDD-2801 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 4 |
| White | 16 | 6 | 6 | 6 | 5 | 6 | 5 | 6 | 5 | 9 | 13 | 6 | 6 | 5 | 5 | 6 | 6 | 5 | 122 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Body mass index(kg/m^2) | Part 1 - Placebo | Part 1 - 50 mg EIDD-2801 | Part 1 - 100 mg EIDD-2801 | Part 1 - 200 mg EIDD-2801 | Part 1 - 400 mg EIDD-2801 | Part 1 - 600 mg EIDD-2801 | Part 1 - 800 mg EIDD-2801 | Part 1 - 1200 mg EIDD-2801 | Part 1 - 1600 mg EIDD-2801 | Part 2 - 200 mg EIDD-2801 (Fasted/Fed) | Part 3 - Placebo | Part 3 - 50 mg EIDD-2801 | Part 3 - 100 mg EIDD-2801 | Part 3 - 200 mg EIDD-2801 | Part 3 - 300 mg EIDD-2801 | Part 3 - 400 mg EIDD-2801 | Part 3 - 600 mg EIDD-2801 | Part 3 - 800 mg EIDD-2801 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 24.80 ± 2.217 | 26.07 ± 2.649 | 23.50 ± 3.501 | 26.68 ± 2.320 | 24.48 ± 2.349 | 25.32 ± 1.847 | 26.45 ± 2.745 | 25.15 ± 1.623 | 23.37 ± 2.954 | 25.38 ± 2.185 | 24.79 ± 2.681 | 22.27 ± 3.371 | 24.97 ± 4.162 | 25.50 ± 3.117 | 24.48 ± 1.901 | 24.32 ± 2.866 | 24.50 ± 3.679 | 24.20 ± 2.504 | 24.81 ± 2.707 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2020 to primary completion in Aug 2020, 4 months.
Results were first posted in Jul 2021, 11 months after primary completion.
Of 35 industry-sponsored phase 1 interventional studies under Coronavirus Infections, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 4 months is below that.
Counting every sponsor, half of 61 studies reached it within 10 months; a quarter within 3 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Molnupiravir
Ridgeback Biotherapeutics, LP